Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate

Next Previous
X
Search
Trial Profile

A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Expanded access; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 09 Jun 2012 Planned number of patients changed from 1400 to 1500 as reported by European Clinical Trials Database.
    • 15 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record (Parent trial: NCT00094029).
    • 25 Oct 2011 Planned initiation date of the extension trial (NCT01459757) is Oct 2011.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top